Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II/III Precision Promise Platform Trial for Metastatic Pancreatic Cancer

Summary

The purpose of this phase II/III platform trial is to compare each investigational arm versus standard of care (SOC) for superiority in overall survival in first and/or second line metastatic pancreatic cancer patients and determine which, if any, patients benefit from each investigational arm.

General Information

NCT#: NCT04229004
Study ID: PanCAN_Precision Promise
Trial Phase: Phase II/III

Trial Sponsor: Pancreatic Cancer Action Network
Therapies Used in This Trial: Nab-paclitaxel, Fluorouracil, Gemcitabine, Oxaliplatin, Irinotecan, Pamrevlumab, Leucovorin, FOLFIRINOX, Spartalizumab, SM-88, Canakinumab

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search